ReproNovo
PrivateLast Round
Series A
May 21, 2025
Total Funding Raised
$65M
Momentum Score
25 /100
Company Overview
ReproNovo is a biopharmaceutical company that develops innovative treatments for reproductive medicine and women's health.
Sector
Healthcare & Life Sciences
Verticals
Medical Devices, Biotechnology
Business Model
B2B
Customer Profile
Hardware Sales, Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
ReproNovo Comps
Public and private peers based on sector, stage, and business model.
ReproNovo Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | May 21, 2025 |
Key People
Founding team and executive leadership
ReproNovo Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| ALSA Ventures | Series A |
| M Ventures | Series A |
| Ysios Capital | Series A |
| AXA IM Alts | Series A |
| BNP Paribas Asset Management Alts | Series A |
| Jeito | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Apr 18, 2026
Monthly visitors grew 291% MoM, reaching 1.6K.
- May 21, 2025
$65M Series A round completed.
ReproNovo Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about ReproNovo's valuation, stock price, and market status.
